Orphazyme A/S (NASDAQ: ORPH) has revealed Monday that it has submitted Marketing Authorisation Application (MAA) for Arimoclomol to European Medicines Agency (EMA). Arimoclomol is the investigational candidate of Orphazyme for the treatment of Niemann-Pick disease Type C (NPC). Marketing Authorisation Application is an